Cadenza Bio Secures $2.44M in Funding, Spearheading Advancements in Multiple Sclerosis Treatment

Cadenza Bio Secures $2.44M in Funding, Spearheading Advancements in Multiple Sclerosis Treatment

Strategic Funding Led by Plains Ventures

In a recent funding round, Plains Ventures took the lead, securing support from notable investors such as the Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures.

Focused Investment for Therapeutic Advancements

The funds acquired are earmarked for a specific and critical cause—Cadenza Bio aims to channel the financial infusion into the development of therapeutic drugs with a primary focus on promoting remyelination in Multiple Sclerosis.

CEO Carol Curtis Guides Cadenza Bio’s Mission

Under the leadership of CEO Carol Curtis, Cadenza Bio is at the forefront of accelerating and facilitating the development of a series of groundbreaking Estrogen Receptor β (ERβ) targeting small-molecule compounds. The company is deeply committed to advancing therapeutic drugs that hold the potential to significantly improve the quality of life for individuals grappling with debilitating diseases.

Origins and Collaborative Research Impact

Established in 2022, Cadenza Bio emerged as a result of a collaboration between SmartHealth Catalyzer in Chicago and Ascend BioVentures in Oklahoma City.

The company holds an exclusive license for technology that originated from a collaborative academic research effort involving Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign (UIUC) and Dr. Seema Tiwari-Woodruff of the University of California, Riverside (UCR).

This research endeavor was partially funded by the National Multiple Sclerosis Society’s Fast Forward commercial research program.

Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn

Read Related News On TDPel Media

Advertisement
Advertisement: Download Vital Signs App (VS App)